SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Phase 2
Active, not recruiting
- Conditions
- Newly Diagnosed Glioblastoma
- Interventions
- Biological: SurVaxM
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- MimiVax, LLC
- Target Recruit Count
- 247
- Registration Number
- NCT05163080
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Fred Hutchinson Cancer Center (FHCC), Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath